Patents are legal documents drawn up by inventors and lawyers and granted by various patent offices around the world, to protect the inventors' intellectual property. The short description accompanying each patent in this Patents section is therefore taken from the legal document as is, with minor corrections for Greek symbols and obvious spelling errors. The patents included in this section may be for material products (defensins or defensin-like peptides or nucleic acid sequences, synthetic or natural) or for novel methods of detecting, quantitating, synthesizing, or delivering antimicrobial peptides/nucleic acid sequences in general. The curators' criterion for inclusion in this section is broader for novel methods than for material products, in the hope that these methods may in future be similarly applied to defensins.

Patents in which the defensins or defensin-like material products and methods as above are not novel, such as biomarker sets containing unmodified defensin or defensin-like peptides or oligonucleotides, are excluded from this section. The exception to such exclusions is where the patent provides other novel defensin-related material products or methods in addition to those non-novel of the biomarker set itself. This exclusion is because the reasonable presence of defensin or defensin-like sequences or indeed any other sequences in patented biomarker sets is necessarily attributed to some prior discovery of disease state correlation with such sequences. The curators have observed therefore that the novel discovery in biomarker-related patents is often the method of biomarker array analysis and validation as well as its resultant implications for diagnostics and prognostics. The expert evaluation of such biomarker analysis and validation is well outside the scope of the Defensins Knowledgebase. The reader is respectfully referred to a biomarker database specific to the disease to perform his own assessment of the validity of the biomarker.

Methods not pertaining to the antimicrobial activity of defensins, but where defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences are suggested in some unambiguous detail to play a useful role in the method, with or without supporting experimental evidence, are included as well in this section. Patents in which natural defensins are up/downregulated in a clearly defined signal transduction pathway as a result of the unrelated patented novel compound or method are also included. And lastly, all patents showing experimental work done with defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences, where such peptides or nucleic acid sequences are not the experimental controls, are included without exception.

The data in this section have been extracted from the academic version of SciFinder Scholar 2007 and from public Google search - a wide range of defensin-related patents are included.


Results 171 - 180 of 333

<< Previous | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | Next >>

Last updated: 20th February 2008

Patent No.: US 056244
Manufacture of milk antimicrobial proteins in transgenic plants for use as feed additives.
Applicant: Huang N, Rodriguez RL, Hagie FE (2003)
The invention is directed to improved animal feed compns. comprising one or more milk proteins with antimicrobial properties produced in the seeds of a transgenic plant and methods of making and using the same.

Patent No.: US 6576755
cDNA and polypeptides human zamp1 polypeptides identified as beta-defensin SAP-1 sequence homologs, sequences and fragments (beta-hairpin loop) thereof.
Applicant: Adler DA, Holloway JL, Baindur N, Beigel-Orme S, Sheppard PO (2003)
The invention provides cDNA mols. encoding full length human zamp1 polypeptides, identified as sequence homologs of beta-defensin SAP-1. The invention also provides cDNA mols. encoding the beta-hairpin loop of said zamp1 polypeptides. The invention further provides the cDNA and amino acid sequences of said human beta-defensin SAP-1 sequence homologs, and their beta-hairpin loops. The invention related that said zamp1 polypeptides have anti-microbial activity and may be potentially used in the study or treatment of microbial infections. In the examples, the gene encoding said zamp1 polypeptide was mapped to human chromosome 8, and one of the zamp1 polypeptides (residues 23 to 67, representing a potential mature form) was synthesized.

Patent No.: US 6545140
DNA encoding an avian beta-defensin and uses thereof.
Applicant: Harmon BG, Jackwood MW, Brockus CW (2003)
An isolated nucleic acid mol. encoding avian beta-defensin is provided. Further provided are compns. comprising an avian beta-defensin, or portions thereof.

Patent No.: JP 088379
Transgenic rice expressing Brassica defensin for multiple disease resistance.
Applicant: Kawada M, Fukumoto F, Nakajima T, Kuroda A (2003)
The invention provides a process of preparation of transgenic rice expressing Brassica defensin. The DNA and protein sequences of the two Brassica defensins were disclosed. The transgenic rice expressing Brassica defensin can be used for multiple disease resistance.

Patent No.: WO 090934
Evaluation of ultraviolet radiation damage to skin using new gene markers, methods and compositions related thereto.
Applicant: Jones BC, Bosko C, Cooper K, McCormick T (2002)
The present invention describes a method for treating and/or evaluating photodamage and/or photoaging of skin caused by exposure to solar UV radiation. The method employs a unique set of marker genes whose expression was newly found to be altered following exposure of skin to UV radiation. The invention provides an advantageous system of identifying and assessing substances that are capable of modulating, e.g., via attenuation, UV radiation induced alteration or change in the expression of at least one of the newly provided marker genes in skin relative to the gene expression level in skin not exposed to UV radiation. Also provided are compns. comprising materials that upon application to skin can modulate the gene expression of at least one gene of the marker gene set after exposure of skin to UV radiation, thereby affording protective and therapeutic effects and treatments for photodamage and photoaging. The potential benefit of, e.g., skin-care, hair care, cosmetic, and personal care agents, and nutritional supplements, as materials having antiphotodamage and/or antiphotoaging properties can be assessed using the present method. Human beta-defensins 2 and 3 are confirmed as being upregulated following exposure of human skin to solar-simulated radiation.

Patent No.: WO 088359
Sequence homologs of genes associated with plant disease and insect resistance and seed composition of grasses and their use in crop improvement.
Applicant: Spangenberg G, Sawbridge TI, Ong EK, Emmerling M (2002)
The present invention relates to nucleic acid fragments encoding amino acid sequences for thionins (TH), thaumatin-like (TL) proteins, elicitor-responsive (ER) proteins and defensins (DEF) in plants and the use thereof for, inter alia, modification of plant defense, disease and/or pest resistance, and/or protein storage, in plants.

Patent No.: WO 085308
Treatment of respiratory and lung diseases with antisense oligonucleotides and a bronchodilating agent.
Applicant: Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D, Miller S, Tang L, Shahabuddin S (2002)
This patent relates to a compn. comprising a carrier, oligonucleotides (oligos) that are antisense to adenosine receptors, and contain low amts. of or no adenosine (A), plus bronchodilating agents. All antisense oligonucleotides designed in accordance with the invention were highly effective at countering or reducing effects mediated by the receptors to which they are targeted. Two antisense phosphorothioated oligos targeting human adenosine A1 receptor mRNA, one targeting adenosine A2b receptor, and two targeting an A3 receptor are capable of countering the effect of exogenously administered adenosine which is mediated by the specific receptor they are targeted to. The activity of the antisense oligos are specific to the target and substitutively fail to inhibit another target. An oligonucleotide wherein the phosphodiester bonds are substituted with phosphorothioate bonds evidenced an unexpected superiority over the phosphodiester antisense oligo. In addn., they result in extremely low or non-existent deleterious side effects or toxicity. This represents 100% success in providing agents that are highly effective and specific in the treatment of bronchoconstriction and/or inflammation. Treatment with antisense oligonucleotides in combination with anti-inflammatory steroid and/or ubiquinones is also provided. These agents and the compn. and formulations provided are suitable for the treatment of respiratory tract, pulmonary and malignant diseases assocd. with bronchoconstriction, respiratory tract inflammation and allergies, impaired airways, including lung disease and diseases whose secondary effects afflict the lungs of a subject, such as allergies, asthma, impeded respiration, allergic rhinitis, pain, cystic fibrosis, pulmonary fibrosis, RDA, COPD, and cancers, among others. The present agents and compn. may be administered preventatively, prophylactically or therapeutically in conjunction with other therapies, or may be utilized as a substitute for therapies that have significant, neg. side effects. The method of the present invention is also practiced with antisense oligonucleotides targeted to many genes, mRNAs and their corresponding proteins in essentially the same manner.

Patent No.: WO 063975
Antimicrobial seed and milk proteins produced in the seeds of plants as feed additive compositions.
Applicant: Huang N, Rodriguez RL, Hagie FE (2002)
The invention is directed to improved animal feed compns. comprising one or more antimicrobial seed and milk proteins produced in the seeds of a monocot plant and methods of making and using the same.

Patent No.: WO 060468
Novel antiviral activities of primate theta defensins and mammalian cathelicidins.
Applicant: Maury W, Stapleton J, Stinski M, Roller R, McCray PB, Tack B (2002)
The present invention relates to the use of anti-viral peptides in the inhibition and treatment of viral infections, in particular infections caused by enveloped viruses. These anti-viral peptides, some natural and others artificial, adopt either amphiphilic alpha-helical or a theta structure where the homodimeric or heterodimer peptides are joined by both cysteine bonds and circularization of the peptides. These agents may be used alone or in combination with more traditional anti-viral pharmaceuticals.

Patent No.: WO 044736
Adhesion protein, protease, and protease inhibitor mutations and methods for diagnosis and treatment of epithelial cell adhesion-associated diseases.
Applicant: Tazi-Ahnini R, Bavik C, Ward S, Duff G, Cork M (2002)
We disclose a method of diagnosis of a disease, or susceptibility to a disease associated with abnormal cell-cell adhesion between epithelial cells, the method comprising detection of a mutation in a nucleic acid encoding an adhesion protein, a protease, or a protease inhibitor of an individual. Thus, the underlying cause of various skin diseases was shown to be the breakdown in regulation of proteolyis of adhesion proteins leading to an increased, decreased, or otherwise abnormal adhesion between corneocytes. Treatment and prevention of such diseases was achieved by modulating the proteolysis of adhesion proteins.